WCN26-9500 Successful Transition from Eculizumab to Iptacopan in a Pediatric Case of C3 Glomerulopathy Refractory to Immunosuppressive Therapy

Read full text Summarise with VIRAT
Authors: Hisashi Kaneda
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

C3 glomerulopathy (C3G) is a subtype of membranoproliferative glomerulonephritis characterized by uncontrolled activation of the complement alternative pathway. Conventional immunosuppressive therapies show limited efficacy, and up to 50% of patients progress to end-stage kidney disease within 10 years. Recently, complement-targeted agents such as eculizumab and iptacopan have become available.

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106418–106418
Publication date
25 March 2026
Language
EN